Aluminum nanoparticles enhance anticancer immune response induced by tumor cell vaccine

Cancer Nanotechnology

Original Paper

Yuanli Zhao¹  Jin Ma²  Yan Hu²  Jinhong Duan²  Haiyan Xu²  Xian-Da Yang²  Jiayan Zhou²  Wei Wang²  Sishen Xie³  Chen Wang⁴  Rui Wang⁴  Shuchang Chen⁵  Zhaohui Zhu⁵  Zhao Sun⁵  Xin Lu⁵ 

[1] Beijing TianTan Hospital, 100050, Beijing, China;Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, 100005, Beijing, China;Institute of Physics, Chinese Academy of Sciences, 100080, Beijing, China;National Center of Nanoscience and Technology, 100080, Beijing, China;Peking Union Medical College Hospital, 100730, Beijing, China;

关键词: Aluminum;    Nanoparticle;    Anticancer;    Immune adjuvant;   

DOI  :  10.1007/s12645-010-0001-5

 received in 2010-01-28, accepted in 2010-02-18,  发布年份 2010

来源: Springer

【 摘 要 】

The application of nanomaterial in cancer treatment is promising and intriguing. Anti-tumor immunotherapy has the potential to significantly improve the prognosis of cancer treatment, though the efficacy of immunotherapy generally needs further improvement. One way to improve the efficacy is using immune adjuvants, but the adjuvants for anticancer immunotherapy have to be more potent than for prophylactic vaccines. Here, we report that compared to conventional alum adjuvant, aluminum oxide nanoparticles (nano-alum) may further enhance the anticancer effects of an immunotherapy that employs tumor cell vaccine (TCV). The average tumor size tends to be lower in animals that receive the combinational treatment of nano-alum and TCV. The anticancer cytotoxicity by the lymphocytes was also significantly higher in the treatment group that received both TCV and nano-alum. These results suggest that nano-alum may potentially serve as a potent immune adjuvant and have prospective applications in anticancer immunotherapy.

【 授权许可】

Unknown   
© Springer-Verlag 2010